MedTrace Logo

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

NCT00567086 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2007-12-04

No results posted yet for this study

Summary

To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute migraine.

Conditions

Interventions

DRUG

TEZAMPANEL

Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)

Sponsors & Collaborators

  • TorreyPines Therapeutics

    lead INDUSTRY

Principal Investigators

  • Michael F. Murphy, M.D., Ph.D. · TorreyPines Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567086 on ClinicalTrials.gov